Механизмы действия препарата Цель Т на патогенетические процессы, лежащие в основе развития остеоартроза


А.А. Марьяновский

Кафедра госпитальной педиатрии № 2 ГБОУ ВПО РНИМУ им. Н.И. Пирогова Минздрава России, Москва
В обзоре приведен анализ механизмов действия различных классов препаратов на патогенез остеоартроза. Рассмотрены основные преимущества и недостатки селективных и неселективных ингибиторов циклооксигеназы. Показано, что в отличие от нестероидных противовоспалительных лекарственных средств препарат Цель Т обладает двойным механизмом действия (действует на циклооксигеназу и на липооксигеназу). Приведены результаты исследований, в которых было доказано, что подобное двойное ингибирование позволяет купировать боль и воспаление, избегая при этом поражения структур пищеварительного тракта.

Литература


  1. Lozada C., del Rio E., Reitberg D, Smith R., Kahn C., Moskowitz R.W. A multi-center double-blind, randomized, controlled trial (db-RCT) to evaluate the effectiveness and safety of co-administered Traumeel® (Tr14) and Zeel® (Ze14) intra-articular (IA) injections versus IA placebo in patients with moderate-to-severe pain associated with OA of the knee. Arthrit. Rheumatol. 2014;66(suppl):S1266.
  2. Lesiak A., Gottwald R., Weiser M. Skutecznosc kuracji preparatem Zeel T w iniekcjach dostawowych okolostawowych i domiesniowych w chorobie zwyrodnieniowej stawow. Medycyna Biologiczna 2001; kwiecien czerwiec zeszyt 2: 30–36 [Effectiveness of the treatment of degenerative joint disease with periarticular, intraarticular and intramuscular injections of Zeel T. Biol. Med. 2001;2:30–6.
  3. Gottwald R., Weiser M. Treatment of osteoarthritis of the knee with Zeel T. Medicina Biologica. 2000;13(4):109–13.
  4. Wodick R.E. Steininger K., Zenner S. The biological treatment of articular affections – results of a study conducted with 498 patients. Biologische Medizin. 1993;3:127–35.
  5. Hieber F. Intra-articular treatment of osteoarthritis and post-traumatic arthralgia with Zeel. Fortschritte der Medizin. 1971;89(18):778–80
  6. Jaggi R., Würgler U., Grandjean F., Weiser M. Dual inhibition of 5-lipoxygenase/cyclooxygenase by a reconstituted homeopathic remedy; possible explanation for clinical efficacy and favourable gastrointestinal tolerability. Inflamm Res. 2004;53(4):150–57.
  7. Birnesser H., Stolt P. The homeopathic preparation Zeel comp. N: A review of the molecular and clinical data. Explore (NY). 2007;3(1):16–22.
  8. Tunon H., Olavsdotter C., Bohlin L. Evaluation of anti-inflammatory activity of some Swedish medicinal plants. Inhibition of prostaglandin biosynthesis and PAF-induced exocytosis. J. Ethnopharmacol. 1995;48:61–76.
  9. Basini G., Santini S.E., Bussolati S., Grasselli F. Sanguinarine inhibits VEGF-induced Akt phosphorylation. Ann. N Y Acad. Sci. 2007;1095:371–76.
  10. Basini G., Bussolati S., Santini S.E., Grasselli F. Sanguinarine inhibits VEGF-induced angiogenesis in a fibrin gel matrix. Biofactors. 2007;29(1):11–8.
  11. Schmolz M. Transforming Growth Factor beta (TGF-β): eine neue Regelstrecke für antiphlogistische Therapien? Biol. Med. 2000;29(1):31–4.
  12. Schmolz M., Heine H. Homöopathische Substanzen aus der antihomotoxischen Medizin modulieren die Synthese von TGF-β1 in menschlichen Vollblutkulturen. Biol. Med. 2001;30(2):61–5.
  13. Stancikova M., Bely M., Svik K., Metelmann H.W., Schmolz M.W., Istok R., Fano R. Effects of Zeel comp. on experimental osteoarthritis in rabbit knee. Rheumatologia. 1999;13(3):101–08.
  14. Weh L., Fröschle G. Incubation in preparations as a means of influencing cartilage mechanics: a mechanical study. Biol. Ther. 1990;8(4):91–3.
  15. Haseeb A., Haggi T.M. Immunopathogenesis of osteoarthritis. Clin. Immunol. 2013;146(3):185–96.
  16. Bonnet C.S., Walsh D.A. Osteoarthritis, angiogenesis and inflammation. Rheumatology. 2005;44:7–16.
  17. Malemud C.J. Anti-cytokine therapy for osteoarthritis. Drugs Aging. 2010;27(2):95–15.
  18. Fernadendes J.S., Materl-Pelletier J., Pelletier J.P. The role of cytokines in osteoarthritis pathophysiology. Biorheology. 2002;39(1–2):237–46.
  19. Pearle A.D., Scanzello C.R., George S., Mandl L.A., DiCarlo E.F., Peterson M., et al. Elevated high-sensitivity C-reactive protein levels are associated with local inflammatory findings in patients with osteoarthritis. Osteoarthritis Cartilage. 2007;15(5):516–23.
  20. Walsh D.A., Pearson C.I. Angiogenesis in the pathogenesis of inflammatory joint and lung diseases. Arthritis Res. 2001;3:147–52.
  21. Mentlein R., Pufe T. New functions of angiogenic peptides in osteoarthritic cartilage. Curr. Rheumatol. Rev. 2005;1:37–45.
  22. Vane J.R., Botting R.M. Anti-inflammatory drugs and their mechanism of action. Inflamm. Res. 1998;47(Suppl 2):S78–87.
  23. Park J.Y., Pillinger M.H., Abramson S.B. Prostaglandin E2 synthesis and secretion: the role of PGE2 synthases. Clin. Immunol. 2006;119(3):229–40.
  24. Giuliano F., Warner T.D. Origins of prostaglandin E2: involvements of cyclooxygenase (COX)-1 and COX-2 in human and rat systems. J. Pharmacol. Exp. Ther. 2002;303(3):1001–06.
  25. Kawabata A. Prostaglandin E2 and pain-an update. Biol. Pharm. Bull. 2011;34(8):1170–73.
  26. Adatia A., Rainsford K.D., Kean W.F. Osteoarthritis of the knee and hip. Part I: aetiology and pathogenesis as a basis for pharmacotherapy. J. Pharm. Pharmacol. 2012;64(5):617–25.
  27. Pountos I., Georgouli T., Bird H., Giannoudis P. Nonsteroidal anti-inflammatory drugs: prostaglandins, indications and side-effects. IJICMR. 2011;3:19–27.
  28. Heller A., Koch T., Schmeck J., van Ackern K. Lipid mediators in inflammatory disorders. Drugs. 1998;55(4):487–96.
  29. Leone S., Ottani A., Bertolini A. Dual acting anti-inflammatory drugs. Curr. Top Med. Chem. 2007;7(3):265–75.
  30. Espanha M.M.
  31. Martel-Pelletier J., Boileau C., Pelletier J.P., Roughley P.J. Cartilage in normal and osteoarthritis conditions. Best Pract. Res. Clin. Rheumatol. 2008;22(2):351–84.
  32. Aigner T., Soeder S., Haag J. IL-1β and BMPs – interactive players of cartilage matrix degradation and regeneration. Eur. Cell. Mater. 2006;12:49–56.
  33. Yasuda T., Poole A.R. A fibronectin fragment induces type II collagen degradation by collagenase through an interleukin-1-mediated pathway. Arthritis Rheum. 2002;46:138–48.
  34. Lozada C., del Rio E., Reitberg D.P., Smith R., Moskowiz W. Risk-benefit of co-administerd Traumeel® (Tr14) and Zeel® (Ze14) intra-articular (IA) injections in patients with moderate-to-severe pain associated with OA of the knee (OAK). Ann. Rheum. Dis. 2015;74(Suppl. 2):Abstract THU0441.


Об авторах / Для корреспонденции


А.А. Марьяновский – д.м.н., проф. Кафедры госпитальной педиатрии №2 ГБОУ ВПО РНИМУим. Н.И. Пирогова Минздрава России, Москва; тел. 8 (495) 434-71-21


Похожие статьи


Бионика Медиа